KURA News and Press, Kura Oncology Inc. From 12/02/20

The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...

Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a re...

Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this event. For further details see: Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow

Kura Oncology, Inc. (KURA) Q3 2020 Earnings Conference Call November 05, 2020 8:00 AM ET Company Participants Pete De Spain - Investor Relations Troy Wilson - President and Chief Executive Officer Marc Grasso - Chief Financial Officer Stephen Dale - Chief Medical Officer Jim Basta - Chief Leg...

Image source: The Motley Fool. Kura Oncology, Inc. (NASDAQ: KURA) Q3 2020 Earnings Call Nov 7, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Kura Oncology, Inc. (KURA) Q3 2020 Earnings Call Transcript

Kura Oncology (KURA): Q3 GAAP EPS of -$0.42 misses by $0.03.$325.4M in Cash, equivalents and investments provide runway into 2023.Press Release For further details see: Kura Oncology EPS misses by $0.03

– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunit...

Kura Oncology (KURA) slumps 15% premarket on light volume in apparent reaction to the release on an abstract on leukemia candidate KO-539 that will be presented at the American Society of Hematology ((ASH)) Annual Meeting in early December.Preliminary results from the first three pa...